The 2026 findings

What changed in ten years of papers on lab animals. Each finding sets 2021 to 2025 against 2011 to 2015.

Updated November 12, 2026.

  • 150,161 papers named a strain, stock, model or engineered line in 2021 to 2025, 110,577 of them a strain, stock or model

  • 1.1 times as many as in 2011 to 2015

  • 26 of 78 strains, stocks and models compared were named in at least 5% more papers in 2021 to 2025 than in 2011 to 2015, and 46 in at least 5% fewer

Compared: the strains, stocks and models with 100 papers or more in one period and 10 or more in each. A substrain's papers count toward its parent strain.

8 findings

A finding stays on this page only while the data support it.

C57BL/6 passed Sprague-Dawley as the strain papers name most

Papers in each period

  • C57BL/6 1.6 times as many
    2011 to 2015
    17,670
    2021 to 2025
    28,313
  • Sprague-Dawley about the same
    2011 to 2015
    18,340
    2021 to 2025
    18,394

Sprague-Dawley led in 2011 to 2015 with 18,340 papers.

C57BL/6 led in 2021 to 2025 with 28,313 papers.

Every strain

Mice gained papers while rats lost them

Papers in each period

  • Mouse 1.4 times as many
    2011 to 2015
    255,811
    2021 to 2025
    349,291
  • Rat 10% fewer
    2011 to 2015
    153,182
    2021 to 2025
    137,802

Papers on mice: 1.4 times as many.

Papers on rats: 10% fewer.

Every species

18 times as many papers name CRISPR near a word for a lab animal

Papers in each period

  • CRISPR-made 18 times as many
    2011 to 2015
    208
    2021 to 2025
    3,640

From 208 papers in 2011 to 2015 to 3,640 in 2021 to 2025, on any species.

A paper counts when it names CRISPR near a word for the animal, so papers that used CRISPR on mouse or rat cells, not to make animals, count too.

Engineered lines

Of the 78 strains compared, 5xFAD gained papers fastest

Papers in each period

  • 5xFAD 7.7 times as many
    2011 to 2015
    170
    2021 to 2025
    1,315
  • APP/PS1 2.7 times as many
    2011 to 2015
    733
    2021 to 2025
    1,966
  • Tg2576 64% fewer
    2011 to 2015
    387
    2021 to 2025
    141

Among the strains, stocks and models with 100 papers or more in one period and 10 or more in each, 5xFAD, a mouse model of Alzheimer's disease, grew fastest: 7.7 times as many papers.

APP/PS1: 2.7 times as many papers. Tg2576: 64% fewer papers.

Rising and falling

NSG mice gained papers while SCID and NOD/SCID mice lost them

Papers in each period

  • NSG 1.8 times as many
    2011 to 2015
    442
    2021 to 2025
    812
  • SCID mouse 62% fewer
    2011 to 2015
    1,195
    2021 to 2025
    457
  • NOD/SCID 50% fewer
    2011 to 2015
    1,007
    2021 to 2025
    501

NSG: 1.8 times as many papers.

SCID: 62% fewer papers. NOD/SCID: 50% fewer papers.

Rising and falling

Cre-lox lines gained papers while transgenic lines lost them

Papers in each period

  • Cre-lox 1.6 times as many
    2011 to 2015
    4,203
    2021 to 2025
    6,537
  • Transgenic 32% fewer
    2011 to 2015
    15,717
    2021 to 2025
    10,651

Cre-lox: 1.6 times as many papers.

Transgenic: 32% fewer papers.

Engineered lines

Zebrafish papers nearly doubled

Papers in each period

  • Zebrafish 1.9 times as many
    2011 to 2015
    10,576
    2021 to 2025
    19,889

From 10,576 papers in 2011 to 2015 to 19,889 in 2021 to 2025: 1.9 times as many.

Zebrafish

Papers naming a strain or line grew more slowly than papers on lab animals

Papers in each period

  • Papers on lab animals 1.2 times as many
    2011 to 2015
    496,368
    2021 to 2025
    597,770
  • Papers that name a strain or line 1.1 times as many
    2011 to 2015
    138,387
    2021 to 2025
    150,161

Papers on lab animals: 1.2 times as many.

Papers that name a strain, stock, model or engineered line: 1.1 times as many.

Their share of animal papers went from 27.9% to 25.1%.

Every strain

More data

Counts are papers in PubMed, with species and research areas from PubTator 3. Courtesy of the U.S. National Library of Medicine. NLM has not endorsed these pages or ConductColony. How we count, downloads and attributions.